New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

• Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels
• Complete proteinuria remission (UPCR ≤0.5 g/g) achieved in one-third of patients and sustained through one year
• Two indirect treatment comparisons indicate that EMPAVELI was superior to iptacopan in reducing proteinuria and achieving the composite renal endpoint in patients with C3G

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare and debilitating kidney diseases.

Among seven EMPAVELI presentations at the upcoming American Society of Nephrology (ASN) Kidney Week, the new results build on previous data showing durable reductions in proteinuria and stable kidney function over one year with EMPAVELI.

“These results further reinforce EMPAVELI’s ability to deliver meaningful, lasting benefits for patients with C3G and primary IC-MPGN, with consistent efficacy across patient groups,” said Peter Hillmen, M.B. Ch.B., Ph.D., chief medical advisor, rare disease, Apellis. “As the only approved treatment for C3G and primary IC-MPGN in patients 12 years and older, EMPAVELI has the potential to transform care for people living with these rare diseases, who have a high risk of kidney failure.”

New One-Year Phase 3 VALIANT Data Reinforce EMPAVELI’s Robust and Sustained Treatment Effect

• Maintained proteinuria reduction regardless of immunosuppressant use or baseline proteinuria levels: Through one year, EMPAVELI sustained the significant 68% proteinuria reduction versus placebo (p